麥迪衛康健康醫療管理科技股份有限公司（「本公司」，連同其附屬公司統稱「本集 團」）董事會（「董事會」）謹此宣佈，謹定將於2025年3月26日（ 星期三 ）舉行董事會 會議，藉以審議及批准本集團截至2024年12月31日止年度之年度業績及其發佈， 考慮建議派發末期股息（ 如有 ），以及處理任何其他事項。 香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或 任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Mediwelcome Healthcare Management & Technology Inc. 麥 迪 衛 康 健 康 醫 療 管 理 科 技 股 份 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：2159） 董事會會議召開日期 於本公告日期，本公司執行董事為施煒先生、楊為民先生、王亮先生及劉桂金女 士；本公司非執行董事為劉夏先生；以及本公司獨立非執行董事為宋瑞霖先生、 David Zheng Wang先生及楊曉曦先生 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或 任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 （股份代號：2159） 內幕消息 Mediwelcome Healthcare Management & Technology Inc. 麥 迪 衛 康 健 康 醫 療 管 理 科 技 股 份 有 限 公 司 （於開曼群島註冊成立的有限公司） 本 公 告 由 麥 迪 衛 康 健 康 醫 療 管 理 科 技 股 份 有 限 公 司（「 本 公 司 」）根 據 上 市 規 則 第 13.09 條及香港法例第571章證券及期貨條例第XIVA部內幕消息條文（ 定義見上市 規則 ）而作出。 茲提述日期為2020年12月31日的招股章程。除另有指明外，本公告所用詞彙與招 股章程所界定者具相同涵義。 現有合約安排 本公司主要從事提供心腦血管疾病綜合醫療營銷解決方案。作為本公司主要業務 的一部分，其通過北京麥迪衛康提供互聯網醫院服務，其中包括視頻製作服務及 ...

Revenue and Growth - Registered doctors increased to 51,833, up approximately 5.2% from 2023[4] - Registered patients reached 298,856, representing a growth of about 13.3% compared to 2023[5] - Online consultations grew to 384,115, marking a significant increase from the previous year[4] - Revenue from medical conference services was RMB 76,133,000, accounting for 54.1% of total revenue, up from RMB 71,592,000 in 2023[7] - Marketing strategy and consulting services generated RMB 53,096,000, representing 37.8% of total revenue, down from RMB 58,927,000 in 2023[7] - Digital marketing solutions revenue increased to RMB 7,496,000, making up 5.3% of total revenue, compared to RMB 6,102,000 in 2023[7] - The total revenue for the six months ended June 30, 2024, was RMB 140,670,000, a decrease from RMB 146,923,000 in 2023[7] - Revenue from medical conference services increased by approximately 6.3% from about RMB 71.6 million to approximately RMB 76.1 million, attributed to projects delayed due to the COVID-19 pandemic[8] - Revenue from marketing strategy and consulting services decreased by approximately 9.9% from about RMB 58.9 million to approximately RMB 53.1 million, reflecting a slowdown in demand[9] - Revenue from digital marketing solutions increased by approximately 22.8% from about RMB 6.1 million to approximately RMB 7.5 million, driven by a focus on higher-margin digital marketing projects[10] - Revenue from patient education and self-testing services decreased by approximately 38.7% from about RMB 2.8 million to approximately RMB 1.7 million, due to reduced economic activity in China[11] - Revenue from CRO services decreased by approximately 71.8% from about RMB 5.9 million to approximately RMB 1.7 million, also reflecting reduced economic activity[12] Financial Performance - Overall gross profit increased by approximately RMB 1.8 million to about RMB 20.7 million, with a gross profit margin rising from 12.9% to 14.7%[14] - Other income, gains, and losses decreased by approximately 74.9% from about RMB 3.2 million to approximately RMB 0.8 million, primarily due to a reduction in VAT refunds[15] - R&D expenses decreased by approximately 38.5% from about RMB 19.6 million to approximately RMB 12.1 million, due to reduced spending on R&D projects[18] - Selling expenses decreased by approximately 36.9% from about RMB 11.5 million to approximately RMB 7.3 million, mainly due to reduced employee costs[16] - Financial costs decreased by approximately 29.7% from RMB 0.8 million to RMB 0.5 million due to early termination of leases[19] - Income tax expenses increased to approximately RMB 0.6 million from RMB 0.1 million, primarily due to insufficient tax provision and reduced tax relief on qualified R&D expenses[19] - The net loss for the period decreased by approximately 39.7% from RMB 38.0 million to RMB 23.0 million, driven by an increase in gross profit of RMB 1.8 million and a reduction in R&D and sales expenses of RMB 7.5 million and RMB 4.3 million respectively[19] - Other comprehensive income recorded was approximately RMB 3.8 million, compared to a loss of RMB 1.6 million in the previous period, mainly due to unrealized gains from investments in unlisted equity securities[19] - The group reported a comprehensive loss of RMB 18.4 million for the six months ended June 30, 2024, compared to a loss of RMB 37.2 million for the same period in 2023[31] - The group reported a pre-tax loss of RMB 22,348,000 for the six months ended June 30, 2024, compared to a loss of RMB 38,031,000 for the same period in 2023, representing a 41.4% improvement[44] - The group’s operating loss for the reporting period was RMB 23,139,000, an improvement from RMB 41,181,000 in the previous year, marking a 43.8% reduction[44] Assets and Liabilities - Trade receivables decreased from approximately RMB 56.9 million to RMB 49.3 million as part of the strategy to scale down lower-margin projects[19] - Trade payables decreased from approximately RMB 32.3 million to RMB 26.5 million, aligning with the reduction in revenue[20] - The company's cash and cash equivalents increased by approximately 2.6% from RMB 80.4 million to RMB 82.4 million[23] - The total outstanding lease liabilities decreased from approximately RMB 9.6 million to RMB 5.5 million[24] - The group's total assets as of June 30, 2024, amount to RMB 211.5 million, a slight decrease from RMB 214.3 million as of December 31, 2023[32] - The group's current liabilities total RMB 109.7 million as of June 30, 2024, compared to RMB 92.3 million as of December 31, 2023[33] - The group’s total non-current assets are primarily located in China, with no geographical segments reported due to the nature of operations[43] Cash Flow and Investments - The company reported a net cash outflow from operating activities of RMB (4,952) thousand for the six months ended June 30, 2024, compared to RMB (8,264) thousand for the same period in 2023, indicating an improvement in operational cash flow[36] - The company invested RMB (32,500) thousand in financial assets measured at fair value through profit or loss during the period, a significant decrease from RMB (117,396) thousand in the previous year[36] - The net cash generated from investing activities was RMB 11,485 thousand, a recovery from a net cash outflow of RMB (45,896) thousand in the same period last year[36] - The company repaid bank loans amounting to RMB (21,698) thousand during the financing activities, indicating a focus on reducing debt[36] Shareholder Information - The company’s major shareholders include Mr. Shi Zhaohua, who holds a beneficial interest of 54.26% in the company[80] - The company’s major shareholders include Liu Ze Investment, Shun Jia Investment, Tai Zhi Feng Investment, and He Hui Wan Yi Investment, each holding 51.76% of the shares, totaling 103,519,000 shares[84] - Zhang Yitao holds 25,415,000 shares, representing 54.26% of the total 108,519,000 shares in the controlled corporation[84] - The total number of issued shares as of June 30, 2024, is 200,000,000[84] - The company has a significant concentration of ownership among its major shareholders, indicating potential influence over corporate decisions[86] Regulatory and Market Environment - Due to Chinese regulations, foreign investors are prohibited from holding equity in entities providing video production services, leading the company to establish contractual arrangements to conduct business in China[89] - The revised regulations on foreign investment in telecommunications enterprises have created significant uncertainty regarding the requirements for foreign investors in value-added telecommunications services[91] - The company is actively conducting feasibility studies for overseas market expansion and has applied for trademark registration outside of China[92] Future Plans and Strategies - The company plans to deepen the integration of AIGC technology with clinical practices in the second half of 2024[6] - The company aims to enhance its internet medical platform to meet the growing demands of stakeholders in the healthcare industry[5] - The company plans to continue its investment in new technologies and market expansion strategies to enhance future growth prospects[38]

Financial Performance - Revenue for the six months ended June 30, 2024, was RMB 140,670 thousand, a decrease of 4.3% compared to RMB 146,923 thousand for the same period in 2023[1] - Gross profit increased to RMB 20,685 thousand, representing a 9.9% increase from RMB 18,906 thousand in the previous year[1] - The net loss for the period was RMB 22,929 thousand, an improvement of 39.7% compared to a net loss of RMB 38,045 thousand in the same period last year[2] - The basic and diluted loss per share for the six months ended June 30, 2024, was RMB 11.60, an improvement from RMB 18.60 in the same period of 2023[2] - For the six months ended June 30, 2024, the group reported a loss before tax of RMB 22,348,000, compared to a loss of RMB 38,031,000 for the same period in 2023, representing a 41.4% improvement[10] - Other income, net of losses, for the six months ended June 30, 2024, was RMB 791,000, significantly lower than RMB 3,150,000 in 2023, marking a decrease of 74.9%[12] - The net loss for the period decreased by approximately 39.7% from RMB 38.0 million to RMB 23.0 million, driven by increased gross profit and reduced expenses[43] Revenue Breakdown - Revenue from medical conference services increased to RMB 76,133,000 in 2024 from RMB 71,592,000 in 2023, reflecting a growth of 6.8%[11] - The group recognized revenue of RMB 134,760,000 at a point in time for the six months ended June 30, 2024, down from RMB 146,744,000 in 2023, indicating a decline of 8.2%[12] - Revenue from medical association services increased by approximately 6.3% from about RMB 71.6 million to approximately RMB 76.1 million, primarily due to projects delayed from the previous year being completed during the reporting period[29] - Revenue from marketing strategy and consulting services decreased by approximately 9.9% from about RMB 58.9 million to approximately RMB 53.1 million, attributed to a slowdown in demand[30] - Revenue from digital marketing solutions increased by approximately 22.8% from about RMB 6.1 million to approximately RMB 7.5 million, driven by a focus on higher-margin projects[31] - Revenue from patient education and self-testing services decreased by approximately 38.7% from about RMB 2.8 million to approximately RMB 1.7 million, due to reduced economic activity in China[32] - CRO services revenue decreased by approximately 71.8% from about RMB 5.9 million to approximately RMB 1.7 million, reflecting decreased economic activity[33] - Revenue from internet hospital services decreased by approximately 64.5% from about RMB 1.6 million to approximately RMB 0.6 million, mainly due to tightened regulations in China[34] Assets and Liabilities - Total assets as of June 30, 2024, were RMB 211,543 thousand, a slight decrease from RMB 214,318 thousand as of December 31, 2023[3] - Current liabilities decreased to RMB 109,719 thousand from RMB 92,271 thousand, indicating a rise in short-term financial obligations[4] - The company's cash and cash equivalents increased to RMB 82,436 thousand from RMB 80,352 thousand, reflecting a stable liquidity position[3] - Trade receivables decreased to RMB 49,276 thousand from RMB 56,864 thousand, suggesting improved collection efficiency[3] - Trade receivables from third parties were RMB 57,052 thousand as of June 30, 2024, compared to RMB 69,396 thousand as of December 31, 2023, indicating a decrease of 17.8%[21] - Trade payables to third parties were RMB 26,548,000 as of June 30, 2024, a decrease from RMB 32,297,000 as of December 31, 2023, indicating a reduction of approximately 17.6%[23] - The asset-to-liability ratio as of June 30, 2024, was 21.3%, up from 17.9% as of December 31, 2023[52] Expenses - Total finance costs decreased to RMB 529 thousand in the first half of 2024 from RMB 752 thousand in the same period of 2023, a reduction of 29.7%[14] - Employee costs amounted to RMB 35,624 thousand for the six months ended June 30, 2024, down from RMB 48,709 thousand in 2023, reflecting a decrease of 26.8%[15] - Sales expenses decreased by approximately 36.9% from RMB 11.5 million to RMB 7.3 million due to reduced employee costs and lower promotional expenses[38] - Administrative expenses decreased by approximately 4.5% from RMB 30.0 million to RMB 28.6 million, primarily due to cost-saving strategies[39] - R&D expenses decreased by approximately 38.5% from RMB 19.6 million to RMB 12.1 million, mainly due to reduced spending on R&D projects[40] - Financial costs decreased by approximately 29.7% from RMB 0.8 million to RMB 0.5 million, attributed to early termination of leases[41] Corporate Governance and Compliance - The company adhered to good corporate governance principles throughout the reporting period[62] - The audit committee reviewed the group's unaudited interim results and discussed risk management and internal control matters[61] - The group has no plans for significant investments or acquisitions of capital assets as of June 30, 2024[59] - The group did not provide any financial assistance or guarantees to associated companies during the reporting period[59] - No financial instruments were used for hedging purposes during the reporting period[60] - The company did not buy, sell, or redeem any of its listed securities during the reporting period[59] Future Outlook and Strategy - The group plans to deepen the integration of AIGC technology with clinical practices in the second half of 2024, aiming to provide precise digital medical communication solutions[26] - The group has successfully integrated AIGC technology and web 3.0 digital technology into its business innovation, enhancing service quality and efficiency[24] - The group has implemented a data asset trading cooperation model to provide high-quality medical knowledge content production experiences for doctors[24]

Financial Performance - Total revenue for 2023 reached RMB 331,308,000, a slight increase from RMB 323,374,000 in 2022, representing a growth of approximately 2.9%[6] - The company reported a gross profit of RMB 29,895,000 for 2023, down from RMB 32,552,000 in 2022, indicating a decrease of about 8.2%[6] - The net loss attributable to the company’s owners for 2023 was RMB 94,096,000, compared to a loss of RMB 89,202,000 in 2022, indicating a worsening of approximately 4.3%[6] - The company recorded a net loss of approximately RMB 96.1 million for the year, compared to a net loss of approximately RMB 93.7 million for the previous year, primarily due to lower gross profit margins and increased impairment of intangible assets[46] - Overall gross profit decreased to approximately RMB 29.9 million from RMB 32.6 million, with gross profit margin declining to 9.0% from 10.1% due to a higher proportion of lower-margin revenue[38] Assets and Liabilities - The total assets decreased to RMB 214,318,000 in 2023 from RMB 317,826,000 in 2022, reflecting a decline of approximately 32.6%[7] - The total liabilities were reduced to RMB 94,351,000 in 2023 from RMB 116,967,000 in 2022, showing a decrease of about 19.5%[7] - Trade receivables decreased from approximately RMB 76.7 million as of December 31, 2022, to approximately RMB 56.9 million as of December 31, 2023, due to more effective credit control measures implemented by the company[50] - Trade payables decreased from approximately RMB 34.0 million as of December 31, 2022, to approximately RMB 32.3 million as of December 31, 2023, reflecting improved cash flow management[51] - The company's cash and bank balances decreased by approximately 42.0%, from approximately RMB 138.6 million as of December 31, 2022, to approximately RMB 80.4 million as of December 31, 2023[56] User Growth and Services - Registered doctors reached 66,573, while registered patients increased to 278,471, marking a growth of approximately 44.1% and 14.4% respectively compared to 2022[10] - Online consultations surged to 344,121, representing a growth of around 27.4% from the previous year[10] - The number of registered doctors on the digital service platform reached 449,480, with online doctor education activities totaling 57,125 sessions and online patient education activities reaching 26,573 sessions[19] - The internet medical platform saw registered doctors increase by 44.13% to 66,573 and patient users grew by 14.4% to 278,471 as of December 31, 2023[20] - The company provides three main services: medical conference services, patient education and self-testing services, and marketing strategy and consulting services[200] Revenue Breakdown - The medical conference services generated RMB 163.7 million, accounting for 49.4% of total revenue, while marketing strategy and consulting services contributed RMB 136.8 million, representing 41.3%[28] - Medical conference services revenue decreased by approximately 1.8% to RMB 163.7 million from RMB 166.8 million in the previous year, primarily due to reduced economic activity in China[29] - Marketing strategy and consulting services revenue increased by approximately 32.8% to RMB 136.8 million from RMB 103.0 million, attributed to the postponement of projects originally scheduled for completion in the previous year due to the COVID-19 pandemic[31] - Digital marketing solutions revenue decreased by approximately 28.1% to RMB 10.5 million from RMB 14.6 million, mainly due to a slowdown in demand consistent with reduced economic activity in China[32] - Patient education and self-testing services revenue decreased by approximately 80.3% to RMB 5.6 million from RMB 28.6 million, primarily due to the company's strategy to scale down lower-margin projects[33] Strategic Initiatives - The company plans to continue innovating digital healthcare service models and enhance intelligent and personalized doctor-patient interaction features[13] - The integration of AI technology and web 3.0 digital technology is expected to drive business growth and improve the quality and efficiency of academic promotion[15] - The company aims to actively participate in the "Healthy China Action" focusing on the prevention and treatment of cardiovascular diseases from 2023 to 2030[13] - The company plans to further expand its innovative smart medical and digital service sectors in 2024 by collaborating with more hospitals and innovative pharmaceutical companies[21] - The integration of AIGC technology into the Giraffe Smart Medical Platform aims to provide precise digital medical communication solutions and enhance the overall healthcare ecosystem[23] Corporate Governance - The board of directors is committed to high levels of corporate governance, ensuring transparency and accountability[79] - The company has maintained compliance with listing rules by appointing at least three independent non-executive directors, constituting at least one-third of the board[91] - The board has established three committees: Audit Committee, Remuneration Committee, and Nomination Committee, each with defined terms of reference[102] - The company has a policy for the rotation and re-election of directors, ensuring that one-third of the board stands for re-election at each annual general meeting[92] - The independent non-executive directors provide checks and balances within the board, ensuring high standards of regulatory reporting[93] Diversity and Inclusion - The board consists of 8 male directors and no female directors, with 1 American and 7 Chinese nationals[116] - The company aims to achieve gender diversity on its board by December 31, 2024, with a target of at least one female board member[117] - The current gender ratio among employees, including senior management, has improved from 90 males to 100 females last year to 112 males to 100 females this year, indicating progress in gender diversity[118] - The company has established appropriate recruitment actions to consider candidates of different ages, genders, and experiences, recognizing that gender diversity provides a competitive advantage[118] - The company has committed to providing career development opportunities and training resources for female employees to promote them to senior management or board positions[117] Risk Management and Compliance - The audit committee has reviewed the company's corporate governance policies and compliance with legal and regulatory requirements for the year ending December 31, 2023[130] - The risk management system aims to manage risks rather than eliminate them, providing reasonable assurance against significant misstatements or losses[138] - The company has implemented monitoring procedures to prevent unauthorized access and use of insider information[145] - The board has confirmed that there are no significant uncertainties that may severely impact the company's ability to continue as a going concern[147] - The company has established a whistleblowing procedure for employees to confidentially report concerns regarding financial reporting and internal controls[142] Shareholder Communication - The company emphasizes effective communication with shareholders, maintaining ongoing dialogue through annual general meetings and other shareholder meetings[160] - The company has a shareholder communication policy to ensure timely and relevant information is provided to shareholders and potential investors[165] - Any shareholder can request information from the company at any time, provided the information is publicly available[168] - The company’s website is regularly updated with financial reports, performance announcements, and other relevant information for shareholders[167] - Shareholders can submit proposals for consideration at the annual general meeting at least 15 business days prior to the meeting date[155]

Financial Performance - Total revenue for the year ended December 31, 2023, was RMB 331,308,000, an increase of 2.9% compared to RMB 323,374,000 in 2022[3]. - Gross profit for the year was RMB 29,895,000, down 8.1% from RMB 32,552,000 in the previous year[3]. - The company reported a net loss of RMB 96,091,000 for the year, compared to a net loss of RMB 93,743,000 in 2022, reflecting a 2.4% increase in losses[3]. - Basic and diluted loss per share for the year was RMB 49.15, compared to RMB 48.01 in the previous year[3]. - The total comprehensive loss for the year was RMB 80,192,000, an improvement from RMB 99,506,000 in 2022[3]. - The group reported a pre-tax loss of RMB 96,378,000 for 2023, compared to a loss of RMB 91,035,000 in 2022, indicating a year-over-year increase in losses of approximately 4.9%[19]. - The group recognized an impairment loss of approximately RMB 20.4 million for intangible assets in the current year, compared to no impairment loss for the year ended December 31, 2022[72]. - The group reported a tax expense of RMB 24,094,000 for 2023, compared to RMB 22,759,000 in 2022, reflecting an increase in tax liabilities[32]. Revenue Breakdown - Revenue from medical consultation services was RMB 163,680,000 in 2023, down from RMB 166,760,000 in 2022, reflecting a decrease of approximately 1.3%[21]. - The group generated RMB 5,612,000 from patient education and self-testing services in 2023, a significant decline from RMB 28,554,000 in 2022, marking a decrease of about 80.3%[21]. - The revenue from sales strategy consulting services increased to RMB 136,801,000 in 2023, up from RMB 102,977,000 in 2022, showing a growth of approximately 33%[21]. - Revenue from marketing strategy and consulting services rose by approximately 32.8% from about RMB 103.0 million to approximately RMB 136.8 million, attributed to the postponement of projects due to the COVID-19 pandemic[60]. - CRO services revenue increased by approximately 81.4% from about RMB 6.4 million to approximately RMB 11.7 million, driven by an increase in users and demand post-pandemic[64]. - Revenue from digital marketing solutions decreased by approximately 28.1% from about RMB 14.6 million to approximately RMB 10.5 million, primarily due to a slowdown in demand[61]. - Revenue from internet hospital services decreased by approximately 24.9% from about RMB 4.0 million to approximately RMB 3.0 million, mainly due to tightened regulations in China[65]. Expenses and Costs - Research and development expenses decreased to RMB 32,685,000, a reduction of 35.4% from RMB 50,612,000 in 2022[3]. - The company recorded a decrease in selling expenses to RMB 22,335,000, down 12.6% from RMB 25,476,000 in 2022[3]. - Administrative expenses increased slightly to RMB 51,014,000, compared to RMB 50,087,000 in the previous year[3]. - Employee costs increased to RMB 96,425,000 in 2023 from RMB 94,597,000 in 2022, reflecting a rise of approximately 1.9%[26]. - The total employee benefits, including salaries and retirement benefits, amounted to RMB 73,654,000 in 2023, up from RMB 69,863,000 in 2022[26]. - The financial cost for 2023 was RMB 1,304,000, slightly higher than RMB 1,246,000 in 2022, representing an increase of about 4.7%[25]. Assets and Liabilities - Total assets decreased from RMB 317.826 billion in 2022 to RMB 214.318 billion in 2023, a decline of approximately 32.6%[4]. - Total liabilities decreased from RMB 108.076 billion in 2022 to RMB 92.271 billion in 2023, a reduction of about 14.7%[5]. - The net value of total assets after deducting current liabilities decreased from RMB 209.750 billion in 2022 to RMB 122.047 billion in 2023, a decrease of approximately 41.8%[5]. - The company's cash and cash equivalents decreased from RMB 138.571 billion in 2022 to RMB 80.352 billion in 2023, a decline of about 42.0%[4]. - The company's total equity decreased from RMB 200.859 billion in 2022 to RMB 119.967 billion in 2023, a decline of about 40.2%[5]. - The company's current liabilities, including trade payables, decreased from RMB 34.021 billion in 2022 to RMB 32.297 billion in 2023, a reduction of approximately 5.1%[5]. Strategic Focus and Future Plans - The company plans to focus on market expansion and new product development in the upcoming year[2]. - The company is focused on strategic management and operational efficiency to navigate the current financial landscape[7]. - The company aims to enhance digital pharmaceutical market services through data analysis for improved service quality and efficiency[42]. - The company is committed to high-quality development and innovation-driven growth in response to global economic trends[41]. - The company aims to enhance digital and intelligent innovations in medical services in 2024, focusing on improving service quality and expanding business scale[55]. - The company plans to further expand its innovative smart medical and digital healthcare services in 2024 by collaborating with more hospitals and leveraging digital technology to enhance treatment standardization[50]. Digital Transformation and Technology - The company is focusing on leveraging AI technology and web 3.0 digital technology for business innovation and growth[42]. - The company successfully applied AI-generated content (AIGC) technology across its platforms, enhancing patient education services and improving communication efficiency between doctors and patients[43]. - The launch of web 3.0 digital technology in November 2023 aims to assist physicians in establishing digital assets and provide a platform for rights confirmation and transaction of medical content[45]. - The integration of the Long Neck Deer Internet Hospital platform and the Medical Management platform will provide more effective digital content and clinical decision support systems for healthcare institutions[51]. - The company has established deep connections with physicians and patients through new tools like apps and WeChat, facilitating the provision of medical knowledge and health management services[46]. Governance and Compliance - The company has adopted good corporate governance principles and complies with the new listing rules effective until December 31, 2023[112]. - The audit committee, consisting of three independent non-executive directors, has reviewed the group's annual performance for the year ending December 31, 2023[117]. - The annual performance announcement and annual report will be published on the Hong Kong Stock Exchange and the company's website[120].

目 錄 | 公 | 司 | 資 | 料 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 業 | 務 | 亮 | 點 | | | | | | | 4 | | 業 | 務 | 回 | 顧 | | | | | | | 5 | | 管 | 理 | 層 | 討 | 論 | 及 | 分 | 析 | | | 9 | | 簡 | 明 | 綜 | 合 | 全 | 面 | 收 | 益 | 表 | | 18 | | 簡 | 明 | 綜 | 合 | 財 | 務 | 狀 | 況 | 表 | | 19 | | 簡 | 明 | 綜 | 合 | 權 | 益 | 變 | 動 | 表 | | 21 | | 簡 | 明 | 綜 | 合 | 現 | 金 | 流 | 量 | 表 | | 22 | | 簡 | 明 | 綜 | 合 | 財 | 務 | 報 | 表 | 附 | 註 | 23 | | 其 | 他 | 資 | 料 | | | | | | | 41 | 2 4 5 9 公司資料 董事會 執行董事： 施煒先生 （董事長） 楊為 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容 概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就 因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損 失承擔任何責任。 Mediwelcome Healthcare Management & Technology Inc. 麥 迪 衛 康 健 康 醫 療 管 理 科 技 股 份 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：2159） 截 至2023年6月30日 止 六 個 月 中 期 業 績 公 告 麥迪衛康健康醫療管理科技股份有限公司（「本公司」）董事（「董事」）會（「董 事會」）欣然宣佈本公司及其附屬公司（統稱「我們」或「本集團」）截至2023年 6月30日 止 六 個 月（「報 告 期」）的 未 經 審 核 綜 合 中 期 業 績，連 同2022年 同 期 的比較數字如下： 簡明綜合全面收益表 截至2023年6月30日止六個月 截至6月30日止六個月 2023年 2022年 附註 人民幣千元 人民幣千元 （未經審核） （未經審核） 收入 3 146,923 172,461 銷售成本 (128,01 ...

Financial Performance - Total revenue for 2022 was RMB 323.374 million, a decrease of approximately 54.4% compared to RMB 708.358 million in 2021[6] - Gross profit for 2022 was RMB 32.552 million, down from RMB 93.596 million in 2021, reflecting a gross margin decline[6] - The company reported a loss before tax of RMB 91.035 million in 2022, compared to a profit of RMB 5.588 million in 2021[6] - The total equity as of December 31, 2022, was RMB 200.859 million, down from RMB 293.487 million in 2021, reflecting a significant reduction in shareholder equity[7] - The company's revenue decreased by approximately 54.3% from about RMB 708.4 million in 2021 to approximately RMB 323.4 million in 2022[27] - The revenue from medical conference services was RMB 166.76 million, accounting for 51.6% of total revenue in 2022[27] - Medical conference services revenue decreased by approximately 60.7% from RMB 424.2 million for the year ended December 31, 2021, to approximately RMB 166.8 million for the year ended December 31, 2022, primarily due to ongoing pandemic impacts and temporary lockdowns in several provinces in China[28] - Marketing strategy and consulting services revenue decreased by approximately 15.0% from RMB 121.2 million for the year ended December 31, 2021, to approximately RMB 103.0 million for the year ended December 31, 2022, attributed to the prolonged economic slowdown caused by COVID-19[29] - Patient education and self-testing services revenue decreased by approximately 81.2% from RMB 152.1 million for the year ended December 31, 2021, to approximately RMB 28.6 million for the year ended December 31, 2022, due to the ongoing pandemic and temporary lockdowns[30] - Overall gross profit decreased from approximately RMB 93.6 million for the year ended December 31, 2021, to approximately RMB 32.6 million for the year ended December 31, 2022, with gross profit margin declining from 13.2% to 10.1%[35] - The company recorded a loss of approximately RMB 93.7 million for the year ended December 31, 2022, compared to a profit of approximately RMB 5.2 million for the year ended December 31, 2021, primarily due to reduced gross profit and decreased government subsidies[43] Assets and Liabilities - Total assets as of December 31, 2022, were RMB 317.826 million, a decrease from RMB 366.700 million in 2021[7] - Total liabilities increased to RMB 116.967 million in 2022 from RMB 73.213 million in 2021, indicating a rise in financial obligations[7] - Trade receivables decreased from approximately RMB 84.2 million as of December 31, 2021, to approximately RMB 76.7 million as of December 31, 2022, attributed to reduced sales due to the resurgence of the pandemic and temporary lockdowns in multiple provinces in China[45] - Trade payables increased from approximately RMB 27.4 million as of December 31, 2021, to approximately RMB 34.0 million as of December 31, 2022, mainly due to delayed payment processes caused by the pandemic[48] - The group's cash and bank balances decreased by approximately 16.2%, from approximately RMB 165.3 million as of December 31, 2021, to approximately RMB 138.6 million as of December 31, 2022[53] - The group’s net current assets were approximately RMB 143.2 million as of December 31, 2022, down from approximately RMB 218.0 million as of December 31, 2021[52] - The group’s asset-liability ratio was 4.5% as of December 31, 2022, compared to zero as of December 31, 2021[55] Business Development and Strategy - New business revenue from digital marketing solutions reached RMB 14.6 million, with registered doctors increasing to 46,190 and registered patients to 243,418, representing growth rates of approximately 50.2% and 180.7% respectively compared to 2021[10] - The company aims to enhance its business scale by providing innovative technology support and efficient marketing solutions through its digital platforms in 2023[20] - The company plans to focus on expanding its services in oncology, respiratory, and chronic kidney disease areas, leveraging favorable health policies and internal resources[21] - The company is integrating AIGC into its Giraffe Smart Medical Platform to enhance its service offerings and attract stakeholders in the healthcare industry[17] - The company continues to explore innovative internet healthcare models, including online consultations and electronic prescriptions, to create a closed-loop business model[23] - The company is considering strategic acquisitions to enhance its service offerings, with a budget of $100 million allocated for potential mergers and acquisitions[165] - The management emphasized a focus on improving customer relationship management, which is expected to boost user retention rates by 5%[165] - The company is investing $30 million in research and development for new technologies aimed at enhancing user experience and operational efficiency[165] Corporate Governance - The company has established a strong corporate governance framework to protect shareholder interests and enhance corporate value[71] - The board comprises a mix of executive, non-executive, and independent non-executive directors, ensuring compliance with listing rules[83] - Independent non-executive directors provide effective independent judgment and oversight within the board[86] - The board consists of 11 directors, with 1 female director, representing 9% gender diversity[110] - The company has increased its employee gender ratio from 70 males to 100 females last year to 90 males to 100 females this year, indicating progress in gender diversity[110] - The Nomination Committee will set measurable targets to implement the board diversity policy and monitor progress towards these targets[107] - The board's composition includes 3 American directors and 8 Chinese directors, reflecting a diverse ethnic representation[109] - The company emphasizes the importance of board diversity for effective corporate governance and strategic goals[104] Risk Management and Compliance - The Board is responsible for evaluating the effectiveness of the risk management and internal control systems at least annually, confirming their effectiveness for the year ended December 31, 2022[129] - The company engaged an external internal control consultant to review its internal audit functions and identify deficiencies for improvement, confirming no significant defects in the internal control system[129] - The company has established a whistleblowing procedure for employees to confidentially report concerns regarding financial reporting and internal controls[130] - The Audit Committee reviewed the company's corporate governance policies and compliance with legal and regulatory requirements for the year ended December 31, 2022[117] - The company has adopted a set of guidelines for securities trading by employees, which are not less stringent than the standard code, and confirmed compliance by all directors from the listing date until December 31, 2022[123] Shareholder Communication - The company has established a shareholder communication policy to ensure timely and relevant information is provided to shareholders[152] - The board of directors will review the effectiveness of the shareholder communication policy regularly[154] - The company encourages electronic communication with shareholders to reduce environmental impact and improve information dissemination[154] - The company maintains effective communication with shareholders through various channels, including annual general meetings[149] - Shareholders can propose resolutions at the annual general meeting, provided they submit their proposals in writing at least 15 business days before the meeting[143] - The company will hold a special general meeting if requested by shareholders holding at least 10% of the voting shares[141] - The company’s website is regularly updated with financial reports and other relevant information for shareholders[156]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告 全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 Mediwelcome Healthcare Management & Technology Inc. 麥 迪 衛 康 健 康 醫 療 管 理 科 技 股 份 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：2159） 截 至2022年12月31日 止 年 度 的 全 年 業 績 公 告 麥迪衛康健康醫療管理科技股份有限公司（「麥迪衛康」或「本公司」）董事（「董事」） 會（「董事會」）欣然宣佈本公司及其附屬公司（統稱「本集團」）截至2022年12月31 日止年度（「本年度」或「報告期」）的經審核綜合全年業績，連同截至2021年12月 31日止年度的比較數字如下： ...